Neos Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018; Provides Sales Guidance for the Fourth Quarter and Full Year of 2018
The company expects its revenue prescript could increase to $120 to $130 range for Adzenys by the end of 2018 and will be approaching for $100 for Cotempla in the fourth quarter. The company plans to spend roughly $0.25 million -- around $250,000, and that will probably be fairly evenly spread throughout the year. It's still within the overall guidance the company had given for R&D spend for this year 2018.